secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-TECHNE Corp (TECH)
CIK:        0000842023
Form:       8-K
Filed at:   2022-05-04T23:59:59+00:00
Accession:  0001558370-22-006932
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Techne Q3 FY2022 revenue $290.4M (+17% organic), record adj. EPS $2.14
--------------------------------------------------------------------------

- Q3 organic revenue +17% to $290.4M (reported +19%); YTD organic +18% to $817.4M.
- Record adjusted EPS $2.14 (GAAP EPS $1.48) vs $1.80 prior year.
- Protein Sciences organic +16%; Diagnostics & Genomics organic +19%.
- Declared quarterly dividend $0.32/share, payable May 27 to holders of record May 16.
- Announced exclusive agreement with Thermo Fisher to commercialize ExoTRU kidney transplant test.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/842023/000155837022006932/0001558370-22-006932-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/842023/000155837022006932/tmb-20220504x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-006932

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer